Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) Chairman Jeffrey M. Leiden sold 132,079 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 25th. The shares were sold at an average price of $281.38, for a total transaction of $37,164,389.02. Following the completion of the transaction, the chairman now owns 2,423 shares of the company’s stock, valued at $681,783.74. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Vertex Pharmaceuticals Stock Performance
Vertex Pharmaceuticals stock opened at $286.99 on Thursday. The company has a current ratio of 4.75, a quick ratio of 4.60 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average of $275.86 and a 200-day moving average of $258.44. The firm has a market cap of $73.40 billion, a P/E ratio of 30.21, a P/E/G ratio of 2.08 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $176.36 and a 1-year high of $296.84.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its earnings results on Thursday, May 5th. The pharmaceutical company reported $3.16 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.01). The firm had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Vertex Pharmaceuticals had a return on equity of 32.24% and a net margin of 30.84%. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.54 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 12.46 EPS for the current year.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on VRTX shares. Morgan Stanley upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating and set a $250.00 price objective for the company in a research note on Tuesday, May 3rd. Cowen upped their price target on shares of Vertex Pharmaceuticals from $305.00 to $310.00 and gave the stock an “outperform” rating in a report on Monday, June 13th. Wells Fargo & Company upped their target price on shares of Vertex Pharmaceuticals from $300.00 to $305.00 in a research report on Friday, May 6th. Argus upped their target price on shares of Vertex Pharmaceuticals from $275.00 to $280.00 and gave the stock a “buy” rating in a research report on Monday, June 13th. Finally, StockNews.com assumed coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $287.68.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- The MarketBeat Podcast: Portfolio Management in Market Downturns
- Can These Two Airline Stocks Overcome Gravity And Fly Higher?
- Shopify Stock Rallies Despite Quarterly Loss
- Two Automation Stocks The Institutions Are Buying
- Can Owens-Corning Insulate Your Portfolio?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.